Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) : Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210
AMD11070 binds to the chemokine receptor CXCR4, with anti-HIV-1 activity in vitro and in vivo. We conducted a phase IB/IIA proof-of-concept dose-escalating, open-label study to determine safety and antiviral activity of AMD11070 administered over 10 days to HIV-1-infected participants who harbored CXCR4-tropic virus. Primary endpoints were ≥1 log10 rlu (relative luminescence units) reduction in CXCR4-tropic virus during 10 days of AMD11070 treatment or in the 7 days following treatment discontinuation, rlu changes over 10 days of treatment, and safety. Plasma pharmacokinetic parameters, HIV-1 RNA, and safety labs were obtained over 90 days of study. The study was stopped early due to emerging AMD11070 animal toxicity data. Six HIV-infected participants with plasma HIV-1 RNA ≥5,000 copies/mL on no antiretroviral therapy for 14 days before entry were treated. AMD11070 was well-tolerated when administered at 200 mg orally every 12 h for 10 days. All enrolled participants had dual/mixed (D/M) viruses. Reductions of almost 1 log10 rlu or more in CXCR4 virus were seen in three of six participants after 10 days of treatment. No participants had ≥1 log10 decline in plasma HIV-1 RNA from baseline at day 10. No clear relationship between pharmacokinetic parameters and response to therapy (X4 log rlu reduction) was observed. AMD11070 demonstrated in vivo activity as measured by reductions in CXCR4 rlu signal. Despite the finding of discordant rlu and plasma HIV RNA responses in these participants with D/M viruses, exploration of other HIV-1 CXCR4 antagonist therapies is possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
AIDS research and human retroviruses - 35(2019), 8 vom: 12. Aug., Seite 691-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Johnson, Victoria A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.07.2020 Date Revised 04.12.2021 published: Print-Electronic ClinicalTrials.gov: NCT00033163 Citation Status MEDLINE |
|---|
| doi: |
10.1089/AID.2018.0256 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297178261 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297178261 | ||
| 003 | DE-627 | ||
| 005 | 20231225091428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/AID.2018.0256 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0990.xml |
| 035 | |a (DE-627)NLM297178261 | ||
| 035 | |a (NLM)31099252 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Johnson, Victoria A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) |b Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210 |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00033163 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AMD11070 binds to the chemokine receptor CXCR4, with anti-HIV-1 activity in vitro and in vivo. We conducted a phase IB/IIA proof-of-concept dose-escalating, open-label study to determine safety and antiviral activity of AMD11070 administered over 10 days to HIV-1-infected participants who harbored CXCR4-tropic virus. Primary endpoints were ≥1 log10 rlu (relative luminescence units) reduction in CXCR4-tropic virus during 10 days of AMD11070 treatment or in the 7 days following treatment discontinuation, rlu changes over 10 days of treatment, and safety. Plasma pharmacokinetic parameters, HIV-1 RNA, and safety labs were obtained over 90 days of study. The study was stopped early due to emerging AMD11070 animal toxicity data. Six HIV-infected participants with plasma HIV-1 RNA ≥5,000 copies/mL on no antiretroviral therapy for 14 days before entry were treated. AMD11070 was well-tolerated when administered at 200 mg orally every 12 h for 10 days. All enrolled participants had dual/mixed (D/M) viruses. Reductions of almost 1 log10 rlu or more in CXCR4 virus were seen in three of six participants after 10 days of treatment. No participants had ≥1 log10 decline in plasma HIV-1 RNA from baseline at day 10. No clear relationship between pharmacokinetic parameters and response to therapy (X4 log rlu reduction) was observed. AMD11070 demonstrated in vivo activity as measured by reductions in CXCR4 rlu signal. Despite the finding of discordant rlu and plasma HIV RNA responses in these participants with D/M viruses, exploration of other HIV-1 CXCR4 antagonist therapies is possible | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AMD11070 | |
| 650 | 4 | |a CXCR4 inhibitor | |
| 650 | 4 | |a HIV-1 entry inhibitors | |
| 650 | 7 | |a Aminoquinolines |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Butylamines |2 NLM | |
| 650 | 7 | |a CXCR4 protein, human |2 NLM | |
| 650 | 7 | |a Heterocyclic Compounds, 1-Ring |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Receptors, CXCR4 |2 NLM | |
| 650 | 7 | |a mavorixafor |2 NLM | |
| 650 | 7 | |a 0G9LGB5O2W |2 NLM | |
| 700 | 1 | |a Cramer, Yoninah S |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenkranz, Susan L |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Klingman, Karin L |e verfasserin |4 aut | |
| 700 | 1 | |a Kallungal, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Coakley, Eoin |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta, Edward P |e verfasserin |4 aut | |
| 700 | 1 | |a Calandra, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Saag, Michael S |e verfasserin |4 aut | |
| 700 | 0 | |a NIH/NIAID AIDS Clinical Trials Group A5210 Protocol Team |e verfasserin |4 aut | |
| 700 | 1 | |a Bedimo, Roger |e investigator |4 oth | |
| 700 | 1 | |a Owens, Susan |e investigator |4 oth | |
| 700 | 1 | |a Ferguson, Elaine |e investigator |4 oth | |
| 700 | 1 | |a Kessels, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Shugarts, David |e investigator |4 oth | |
| 700 | 1 | |a Parrillo, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Upton, Kerry |e investigator |4 oth | |
| 700 | 1 | |a White, V |e investigator |4 oth | |
| 700 | 1 | |a Goldman, Mitchell |e investigator |4 oth | |
| 700 | 1 | |a Zwickl, W |e investigator |4 oth | |
| 700 | 1 | |a Del Rio, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Turkia, Akaki |e investigator |4 oth | |
| 700 | 1 | |a Zadzilk, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Darren Hazelwood, J |e investigator |4 oth | |
| 700 | 1 | |a Lu, Darlene |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS research and human retroviruses |d 1990 |g 35(2019), 8 vom: 12. Aug., Seite 691-697 |w (DE-627)NLM012611727 |x 1931-8405 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2019 |g number:8 |g day:12 |g month:08 |g pages:691-697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/AID.2018.0256 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2019 |e 8 |b 12 |c 08 |h 691-697 | ||